That’s a big deal for patients with HR+/HER2- breast cancer who’ve run out of options after standard treatments fail. The drug targets those with PIK3CA/AKT1/PTEN mutations; about half of all breast cancer patients; offering hope where resistance normally shuts the door. Phase III trial data showed strong progression-free survival and a safety profile that’s already being called "best-in-class." The company’s already locked in a ₹500+ crore deal with Qilu Pharma for China rights, and they’re not stopping at breast cancer; prostate trials are racing ahead too. For Indian med aspirants and biotech watchers: this is why oncology pipelines matter. A single drug like this can shift treatment paradigms; and the next breakthrough could come from your lab bench.